Brandon J. Webb
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Brandon J. Webb has a total of 212 co-authors. Here are the top co-authors by number of shared publications:
- Edward Stenehjem
Department of Medicine, Division of Infectious Diseases, University of Colorado School of Medicine , Aurora, Colorado
7 shared publications - Whitney R. Buckel
Department of Pharmacy, Intermountain Health , Salt Lake City, Utah
7 shared publications Jared Olson
Department of Pharmacy, Primary Children’s Hospital
5 shared publications- John J. Veillette
Department of Pharmacy, Intermountain Medical Center, Murray, UT, USA
5 shared publications Mark Shah
Intermountain Healthcare Emergency Medicine and Trauma Operations, Salt Lake City, UT
5 shared publicationsNancy Grisel
Affiliation Intermountain Healthcare, Enterprise Analytics, Salt Lake City, UT, United States of America
5 shared publications
Latest Publications
- Open Access
- 3 February 2026
- Published by American Society for Microbiology in Microbiology Spectrum
- Vol. 14 (2) , e0170425
Effect of oral beta-lactam dosing on outcomes of bacteremic Gram-negative urinary tract infections: a real-world analysis
Among 452 adult patients with Gram-negative bacteremia from a urinary tract infection source who received oral step-down therapy with highly bioavailable oral beta-lactam, we observed no difference in 60-day recurrence in patients treated with higher consensus-recommended dosing compared to lower, standard dosing (odds ratio = 0.76 [95% confidence interval = 0.43–1.32]), although the directionality of the effect was favorable. The study was limited by inadequate sample size and confounding. Randomized or large observational comparative effectiveness studies are needed. IMPORTANCE: Definitive treatment of Gram-negative bacteremia with oral antibiotic agents is not one size fits all. Use of oral fluoroquinolones and sulfamethoxazole/trimethoprim is evidence-based but carries risk for adverse events. Data supporting the use of oral beta-lactams are mixed, likely in part due to variable agent selection and dosing. This analysis shows that higher, consensus-recommended dosing of highly bioavailable beta-lactam antibiotics was not significantly different from patients treated with lower dosing on 60-day recurrence. Our study was limited by the number of patients with discrete MICs and overinfluence of complicated urinary tract infection on outcomes.
- 3 February 2026
- Published by American Society for Microbiology in Microbiology Spectrum
- Vol. 14 (2) , e0170425
Open AccessEffect of oral beta-lactam dosing on outcomes of bacteremic Gram-negative urinary tract infections: a real-world analysis
Among 452 adult patients with Gram-negative bacteremia from a urinary tract infection source who received oral step-down therapy with highly bioavailable oral beta-lactam, we observed no difference in 60-day recurrence in patients treated with higher consensus-recommended dosing compared to lower, standard dosing (odds ratio = 0.76 [95% confidence interval = 0.43–1.32]), although the directionality of the effect was favorable. The study was limited by inadequate sample size and confounding. Randomized or large observational comparative effectiveness studies are needed. IMPORTANCE: Definitive treatment of Gram-negative bacteremia with oral antibiotic agents is not one size fits all. Use of oral fluoroquinolones and sulfamethoxazole/trimethoprim is evidence-based but carries risk for adverse events. Data supporting the use of oral beta-lactams are mixed, likely in part due to variable agent selection and dosing. This analysis shows that higher, consensus-recommended dosing of highly bioavailable beta-lactam antibiotics was not significantly different from patients treated with lower dosing on 60-day recurrence. Our study was limited by the number of patients with discrete MICs and overinfluence of complicated urinary tract infection on outcomes.
- Open Access
- 20 November 2025
- Published by Cambridge University Press (CUP) in Infection Control & Hospital Epidemiology
- Vol. 47 (2) , 180-188
Interventions to optimize duration of antibiotic therapy and encourage oral transition for uncomplicated gram-negative blood stream infections across a health system
Background: Shorter antibiotic courses and transition to oral therapy for uncomplicated gram-negative bloodstream infections (GN-BSI) are evidence-supported yet remain challenging to implement. Here we report our experience with a GN-BSI antimicrobial stewardship (AS) quality improvement initiative in a large health system. Methods: We implemented two sequential AS interventions in adult patients hospitalized with uncomplicated GN-BSI: (1) mandatory AS review of patients discharging on intravenous (IV) antibiotics (“OPAT review”) and (2) a clinical guideline informing oral antibiotic transition and duration, in our 22-hospital system. We evaluated the initiative from January 2018 to September 2024. Pre- and postimplementation rates of (1) IV antibiotics at discharge and (2) total length of antibiotic therapy were calculated across the following periods: preintervention, after OPAT review, and after guideline implementation. Secondary outcomes included duration p < 0.001) and median length of treatment (13.5 days preintervention to 10.7 days postguideline, p < 0.001). We also observed improvement in durations p < 0.001), oral antibiotic prescriptions, and appropriate dosing (2.8% vs 33.5%, p < 0.001), but no difference in rates of BSI recurrence, mortality, or C. difficile infection. Conclusion: After implementing GN-BSI-focused AS initiatives in our large health system, we observed a shift toward more frequent oral rather than IV antibiotics at discharge, and shorter overall antibiotic durations, without obvious changes in adverse outcomes.
- 20 November 2025
- Published by Cambridge University Press (CUP) in Infection Control & Hospital Epidemiology
- Vol. 47 (2) , 180-188
Open AccessInterventions to optimize duration of antibiotic therapy and encourage oral transition for uncomplicated gram-negative blood stream infections across a health system
Background: Shorter antibiotic courses and transition to oral therapy for uncomplicated gram-negative bloodstream infections (GN-BSI) are evidence-supported yet remain challenging to implement. Here we report our experience with a GN-BSI antimicrobial stewardship (AS) quality improvement initiative in a large health system. Methods: We implemented two sequential AS interventions in adult patients hospitalized with uncomplicated GN-BSI: (1) mandatory AS review of patients discharging on intravenous (IV) antibiotics (“OPAT review”) and (2) a clinical guideline informing oral antibiotic transition and duration, in our 22-hospital system. We evaluated the initiative from January 2018 to September 2024. Pre- and postimplementation rates of (1) IV antibiotics at discharge and (2) total length of antibiotic therapy were calculated across the following periods: preintervention, after OPAT review, and after guideline implementation. Secondary outcomes included duration p < 0.001) and median length of treatment (13.5 days preintervention to 10.7 days postguideline, p < 0.001). We also observed improvement in durations p < 0.001), oral antibiotic prescriptions, and appropriate dosing (2.8% vs 33.5%, p < 0.001), but no difference in rates of BSI recurrence, mortality, or C. difficile infection. Conclusion: After implementing GN-BSI-focused AS initiatives in our large health system, we observed a shift toward more frequent oral rather than IV antibiotics at discharge, and shorter overall antibiotic durations, without obvious changes in adverse outcomes.
- Open Access
- 17 July 2025
- Published by Cambridge University Press (CUP) in Antimicrobial Stewardship & Healthcare Epidemiology
- Vol. 5 (1) , e157
The impact of an intervention to increase follow-up blood cultures for patients with Staphylococcus aureus bacteriuria
Background: Staphylococcus aureus bacteriuria (SABU) may represent bacteremia in a subset of patients. We describe the impact of a microbiology alert recommending follow-up blood cultures (FUBC) for patients with SABU in a large integrated health system. Methods: We conducted a quasi-experimental implementation study in adult ambulatory patients with documented SABU. We excluded patients with confirmed SAB up to 14 days prior to index SABU culture and with blood cultures obtained on the day of SABU. The primary outcome was rate of FUBC (collected between 1 and 5 days of SABU) among all cases of SABU. Secondary outcomes included percentage of patients with early SAB (collected between 1 and 5 days of SABU). We used interrupted time series analysis to compare rates of FUBC pre vs postintervention. Results: A total of 2 540 patients were identified; 1 213 (48%) were male. By the end of the postintervention period, the rate of FUBC (20.6%) had increased by 6.3 percentage points (P = .005) compared to the counterfactual (14.2%) had no intervention taken place (44.5% relative increase). Early SAB detection due to FUBC increased from .6% preintervention to 2.0% postintervention (P = .004). Conclusion: The microbiology alert initiative increased FUBC in patients with SABU by 44%, but the overall rate of FUBC remained low. The intervention increased early SAB detection. Risk-targeted strategies are needed to optimize FUBC collection in patients with SABU.
- 17 July 2025
- Published by Cambridge University Press (CUP) in Antimicrobial Stewardship & Healthcare Epidemiology
- Vol. 5 (1) , e157
Open AccessThe impact of an intervention to increase follow-up blood cultures for patients with Staphylococcus aureus bacteriuria
Background: Staphylococcus aureus bacteriuria (SABU) may represent bacteremia in a subset of patients. We describe the impact of a microbiology alert recommending follow-up blood cultures (FUBC) for patients with SABU in a large integrated health system. Methods: We conducted a quasi-experimental implementation study in adult ambulatory patients with documented SABU. We excluded patients with confirmed SAB up to 14 days prior to index SABU culture and with blood cultures obtained on the day of SABU. The primary outcome was rate of FUBC (collected between 1 and 5 days of SABU) among all cases of SABU. Secondary outcomes included percentage of patients with early SAB (collected between 1 and 5 days of SABU). We used interrupted time series analysis to compare rates of FUBC pre vs postintervention. Results: A total of 2 540 patients were identified; 1 213 (48%) were male. By the end of the postintervention period, the rate of FUBC (20.6%) had increased by 6.3 percentage points (P = .005) compared to the counterfactual (14.2%) had no intervention taken place (44.5% relative increase). Early SAB detection due to FUBC increased from .6% preintervention to 2.0% postintervention (P = .004). Conclusion: The microbiology alert initiative increased FUBC in patients with SABU by 44%, but the overall rate of FUBC remained low. The intervention increased early SAB detection. Risk-targeted strategies are needed to optimize FUBC collection in patients with SABU.
- Open Access
- 3 March 2025
- Published by Cambridge University Press (CUP) in Antimicrobial Stewardship & Healthcare Epidemiology
- Vol. 5 (1) , e73
Evaluation of serial erythrocyte sedimentation rate and C-reactive protein monitoring in infectious disease outpatient parenteral antimicrobial therapy patients
Of 313 patients whose outpatient parenteral antimicrobial therapy was managed by an ID physician, only 39 [12.5%, 95% CI (8.8%–16.1%)] had clinical decisions influenced by erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), or both. ESR/CRP ordering was associated with $530 in excess cost per treatment course (average duration 5.1 weeks) representing a diagnostic stewardship opportunity.
- 3 March 2025
- Published by Cambridge University Press (CUP) in Antimicrobial Stewardship & Healthcare Epidemiology
- Vol. 5 (1) , e73
Open AccessEvaluation of serial erythrocyte sedimentation rate and C-reactive protein monitoring in infectious disease outpatient parenteral antimicrobial therapy patients
Of 313 patients whose outpatient parenteral antimicrobial therapy was managed by an ID physician, only 39 [12.5%, 95% CI (8.8%–16.1%)] had clinical decisions influenced by erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), or both. ESR/CRP ordering was associated with $530 in excess cost per treatment course (average duration 5.1 weeks) representing a diagnostic stewardship opportunity.
- Open Access
- 17 January 2025
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 12 (2) , ofaf012
Evaluation of Daptomycin Use in Outpatients With Methicillin-Sensitive Staphylococcus aureus Bloodstream Infections
Multiple observational studies in methicillin-resistant Staphylococcus aureus and enterococcal infections have suggested that higher doses of daptomycin may be associated with better clinical outcomes. However, optimal daptomycin dosing in methicillin-sensitive S aureus bloodstream infections remains unclear. In this multicentered, retrospective, observational cohort study, we compared standard dose daptomycin (<8 mg/kg) vs high dose (≥8 mg/kg) for methicillin-sensitive S aureus bloodstream infections. In a propensity-weighted model, the composite outcome of treatment failure within 90 days was lower in the high-dose group relative to the standard dose group (odds ratio, 0.496; 95% CI, .306–.804). We did not detect any significant difference in safety outcomes.
- 17 January 2025
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 12 (2) , ofaf012
Open AccessEvaluation of Daptomycin Use in Outpatients With Methicillin-Sensitive Staphylococcus aureus Bloodstream Infections
Multiple observational studies in methicillin-resistant Staphylococcus aureus and enterococcal infections have suggested that higher doses of daptomycin may be associated with better clinical outcomes. However, optimal daptomycin dosing in methicillin-sensitive S aureus bloodstream infections remains unclear. In this multicentered, retrospective, observational cohort study, we compared standard dose daptomycin (<8 mg/kg) vs high dose (≥8 mg/kg) for methicillin-sensitive S aureus bloodstream infections. In a propensity-weighted model, the composite outcome of treatment failure within 90 days was lower in the high-dose group relative to the standard dose group (odds ratio, 0.496; 95% CI, .306–.804). We did not detect any significant difference in safety outcomes.
- 22 October 2024
- Published by Elsevier in Clinical Microbiology and Infection
- Vol. 31 (4) , 651-653
Re: “HANCEK” infective endocarditis: a case for including Neisseria elongata in the HACEK group
- 22 October 2024
- Published by Elsevier in Clinical Microbiology and Infection
- Vol. 31 (4) , 651-653
Re: “HANCEK” infective endocarditis: a case for including Neisseria elongata in the HACEK group
- Open Access
- 27 December 2023
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 11 (2) , ofad657
Oral β-Lactams, Fluoroquinolones, or Trimethoprim-Sulfamethoxazole for Definitive Treatment of Uncomplicated Escherichia coli or Klebsiella Species Bacteremia From a Urinary Tract Source
Fluoroquinolones (FQs) are effective for oral step-down therapy for gram-negative bloodstream infections but are associated with unfavorable toxic effects. Robust data are lacking for trimethoprim-sulfamethoxazole (TMP-SMX) and high-bioavailability β-lactams (HBBLs). In this multicenter observational cohort study, we simulated a 3-arm registry trial using causal inference methods to compare the effectiveness of FQs, TMP-SMX, or HBBLs for gram-negative bloodstream infections oral step-down therapy. The study included adults treated between January 2016 and December 2022 for uncomplicated Escherichia coli or Klebsiella species bacteremia of urinary tract origin who were who were transitioned to an oral regimen after ≤4 days of effective intravenous antibiotics. Propensity weighting was used to balance characteristics between groups. 60-day recurrence was compared using a multinomial Cox proportional hazards model with probability of treatment weighting. Of 2571 patients screened, 648 (25%) were included. Their median age (interquartile range) was 67 (45–78) years, and only 103 (16%) were male. Characteristics were well balanced between groups. Compared with FQs, TMP-SMX had similar effectiveness (adjusted hazard ratio, 0.91 [95% confidence interval, .30–2.78]), and HBBLs had a higher risk of recurrence (2.19 [.95–5.01]), although this difference was not statistically significant. Most HBBLs (70%) were not optimally dosed for bacteremia. A total antibiotic duration ≤8 days was associated with a higher recurrence rate in select patients with risk factors for failure. FQs and TMP-SMX had similar effectiveness in this real-world data set. HBBLs were associated with higher recurrence rates but suboptimal dosing may have contributed. Further studies are needed to define optimal BL dosing and duration to mitigate treatment failures. https://tidbitapp.io/tidbits/oral-beta-lactams-fluoroquinolones-or-trimethoprim-sulfamethoxazole-for-definitive-treatment-of-uncomplicated-escherichia-coli-or-klebsiella-species-bacteremia-from-a-urinary-source
- 27 December 2023
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 11 (2) , ofad657
Open AccessOral β-Lactams, Fluoroquinolones, or Trimethoprim-Sulfamethoxazole for Definitive Treatment of Uncomplicated Escherichia coli or Klebsiella Species Bacteremia From a Urinary Tract Source
Fluoroquinolones (FQs) are effective for oral step-down therapy for gram-negative bloodstream infections but are associated with unfavorable toxic effects. Robust data are lacking for trimethoprim-sulfamethoxazole (TMP-SMX) and high-bioavailability β-lactams (HBBLs). In this multicenter observational cohort study, we simulated a 3-arm registry trial using causal inference methods to compare the effectiveness of FQs, TMP-SMX, or HBBLs for gram-negative bloodstream infections oral step-down therapy. The study included adults treated between January 2016 and December 2022 for uncomplicated Escherichia coli or Klebsiella species bacteremia of urinary tract origin who were who were transitioned to an oral regimen after ≤4 days of effective intravenous antibiotics. Propensity weighting was used to balance characteristics between groups. 60-day recurrence was compared using a multinomial Cox proportional hazards model with probability of treatment weighting. Of 2571 patients screened, 648 (25%) were included. Their median age (interquartile range) was 67 (45–78) years, and only 103 (16%) were male. Characteristics were well balanced between groups. Compared with FQs, TMP-SMX had similar effectiveness (adjusted hazard ratio, 0.91 [95% confidence interval, .30–2.78]), and HBBLs had a higher risk of recurrence (2.19 [.95–5.01]), although this difference was not statistically significant. Most HBBLs (70%) were not optimally dosed for bacteremia. A total antibiotic duration ≤8 days was associated with a higher recurrence rate in select patients with risk factors for failure. FQs and TMP-SMX had similar effectiveness in this real-world data set. HBBLs were associated with higher recurrence rates but suboptimal dosing may have contributed. Further studies are needed to define optimal BL dosing and duration to mitigate treatment failures. https://tidbitapp.io/tidbits/oral-beta-lactams-fluoroquinolones-or-trimethoprim-sulfamethoxazole-for-definitive-treatment-of-uncomplicated-escherichia-coli-or-klebsiella-species-bacteremia-from-a-urinary-source
- 1 May 2023
- Published by Wiley in Journal of Hospital Medicine
- Vol. 18 (8) , 719-723
Effect of tele‐COVID rounds and a tele‐stewardship intervention on antibiotic use in COVID‐19 patients admitted to 17 small community hospitals
Antibiotic stewardship interventions are urgently needed to reduce antibiotic overuse in hospitalized COVID‐19 patients, particularly in small community hospitals (SCHs), who often lack access to infectious diseases (ID) and stewardship resources. We implemented multidisciplinary tele‐COVID rounds plus tele‐antibiotic stewardship surveillance in 17 SCHs to standardize COVID management and evaluate concurrent antibiotics for discontinuation. Antibiotic use was compared in the 4 months preintervention versus 10 months postintervention. Interrupted time‐series analysis demonstrated an immediate decrease in antibiotic use by 339 days of therapy/1000 COVID‐19 patient days (p < .001), and an estimated 5258 antibiotic days avoided during the postintervention period. Thirty‐day mortality was not significantly different, and a significant reduction in transfers was observed following the intervention (23.3% vs. 7.8%, p < .001). A novel tele‐ID and tele‐stewardship intervention significantly decreased antibiotic use and transfers among COVID‐19 patients at 17 SCHs, demonstrating that telehealth is a feasible way to provide ID expertise in community and rural settings.
- 1 May 2023
- Published by Wiley in Journal of Hospital Medicine
- Vol. 18 (8) , 719-723
Effect of tele‐COVID rounds and a tele‐stewardship intervention on antibiotic use in COVID‐19 patients admitted to 17 small community hospitals
Antibiotic stewardship interventions are urgently needed to reduce antibiotic overuse in hospitalized COVID‐19 patients, particularly in small community hospitals (SCHs), who often lack access to infectious diseases (ID) and stewardship resources. We implemented multidisciplinary tele‐COVID rounds plus tele‐antibiotic stewardship surveillance in 17 SCHs to standardize COVID management and evaluate concurrent antibiotics for discontinuation. Antibiotic use was compared in the 4 months preintervention versus 10 months postintervention. Interrupted time‐series analysis demonstrated an immediate decrease in antibiotic use by 339 days of therapy/1000 COVID‐19 patient days (p < .001), and an estimated 5258 antibiotic days avoided during the postintervention period. Thirty‐day mortality was not significantly different, and a significant reduction in transfers was observed following the intervention (23.3% vs. 7.8%, p < .001). A novel tele‐ID and tele‐stewardship intervention significantly decreased antibiotic use and transfers among COVID‐19 patients at 17 SCHs, demonstrating that telehealth is a feasible way to provide ID expertise in community and rural settings.
- Open Access
- 13 April 2023
- Published by American Society for Microbiology in Microbiology Spectrum
- Vol. 11 (2) , e0467422
A Randomized Clinical Trial Testing Hydroxychloroquine for Reduction of SARS-CoV-2 Viral Shedding and Hospitalization in Early Outpatient COVID-19 Infection
Early in the COVID-19 pandemic, no effective treatment existed to prevent clinical worsening of COVID-19 among recently diagnosed outpatients. Hydroxychloroquine received attention as a possible early treatment; however, quality prospective studies were lacking. We conducted a clinical trial to test the ability of hydroxychloroquine to prevent clinical worsening of COVID-19.
- 13 April 2023
- Published by American Society for Microbiology in Microbiology Spectrum
- Vol. 11 (2) , e0467422
Open AccessA Randomized Clinical Trial Testing Hydroxychloroquine for Reduction of SARS-CoV-2 Viral Shedding and Hospitalization in Early Outpatient COVID-19 Infection
Early in the COVID-19 pandemic, no effective treatment existed to prevent clinical worsening of COVID-19 among recently diagnosed outpatients. Hydroxychloroquine received attention as a possible early treatment; however, quality prospective studies were lacking. We conducted a clinical trial to test the ability of hydroxychloroquine to prevent clinical worsening of COVID-19.
- Open Access
A Compound Model of Multiple Treatment Selection with Applications to Marginal Structural Modeling
Methods of causal inference are used to estimate treatment effectiveness for non-randomized study designs. The propensity score (i.e., the probability that a subject receives the study treatment conditioned on a set of variables related to treatment and/or outcome) is often used with matching or sample weighting techniques to, ideally, eliminate bias in the estimates of treatment effect due to treatment decisions. If multiple treatments are available, the propensity score is a function of the adjustment set and the set of possible treatments. This paper develops a compound model that separates the treatment decision into a binary decision: treat or don’t treat; and a potential treatment decision: choose the treatment that would be given if the subject is treated. It is applicable if the treatment set is finite, treatments are given at one time point, and the outcome is observed at a fixed time point. This representation can reduce bias when not all treatments are available to all patients. Multiple treatment stabilized marginal structural weights were calculated with this approach, and the method was applied to an observational study to evaluate the effectiveness of different neutralizing monoclonal antibodies to treat infection with various severe acute respiratory syndrome coronavirus 2 variants.
Open AccessA Compound Model of Multiple Treatment Selection with Applications to Marginal Structural Modeling
Methods of causal inference are used to estimate treatment effectiveness for non-randomized study designs. The propensity score (i.e., the probability that a subject receives the study treatment conditioned on a set of variables related to treatment and/or outcome) is often used with matching or sample weighting techniques to, ideally, eliminate bias in the estimates of treatment effect due to treatment decisions. If multiple treatments are available, the propensity score is a function of the adjustment set and the set of possible treatments. This paper develops a compound model that separates the treatment decision into a binary decision: treat or don’t treat; and a potential treatment decision: choose the treatment that would be given if the subject is treated. It is applicable if the treatment set is finite, treatments are given at one time point, and the outcome is observed at a fixed time point. This representation can reduce bias when not all treatments are available to all patients. Multiple treatment stabilized marginal structural weights were calculated with this approach, and the method was applied to an observational study to evaluate the effectiveness of different neutralizing monoclonal antibodies to treat infection with various severe acute respiratory syndrome coronavirus 2 variants.